Genervon Biopharmaceuticals received FDA approval for a Phase IIb trial of GM604 in ALS last June, and has now announced the successful completion of the trial. GM604 is a hexapeptide derived from neurotrophic factor motorneuronotrophic factor (MTNF), which confers its effect by regulating multiple ALS-associated genes and pathways. Preliminary analysis of the trial data shows that seven out of eight patients exhibited attenuation of disease progression within ten weeks after completion of dosing. The full results of the study will be released later in 2014.
Click here to read the full press release.Share this: